BURZYNSKI RESEARCH INSTITUTE INC (BZYR) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US1231591058
BURZYNSKI RESEARCH INSTITUTE INC financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 0.00 USD |
| Operating income | -1.39 m USD |
| EBIT | -1.39 m USD |
| Net income | -1.39 m USD |
| Diluted EPS – continuing operations | -0.01 USD |
Full history since 1998, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About BURZYNSKI RESEARCH INSTITUTE INC
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. The company was founded in 1977 and is headquartered in Houston, Texas.
More stocks
- Rani Therapeutics Holdings, Inc. (RANI)
- Regen BioPharma Inc (RGBPP)
- ESS Tech, Inc. (GWH)
- Onconetix, Inc. (ONCO)
- SmartKem, Inc. (SMTK)
- Livento Group, Inc. (LIVG)
- Metavesco, Inc. (MVCO)
- Valion Bio, Inc. (VBIO)
- ALKALINE WATER Co INC (WTER)
- Telvantis, Inc. (RDAR)
- ESPORTS ENTERTAINMENT GROUP, INC. (GMBLP)
- Wellchange Holdings Company Limited (WCT)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.